Como a eritrossedimentação tem contribuído nas patologias oncológicas?: uma revisão integrativa
DOI:
https://doi.org/10.34119/bjhrv7n2-472Keywords:
eritrossedimentação, Câncer, neoplasiasAbstract
A eritrossedimentação é amplamente utilizada como marcador inflamatório inespecífico e seu baixo custo e fácil realização permite que esteja entre os exames rotineiros dos pacientes nas mais diversas patologias. As neoplasias são doenças crônicas não transmissíveis e que necessitam de exames laboratoriais durante as diversas fases dos agravos em saúde. Assim, estudos têm sido realizados para verificar a possibilidade desse marcador contribuir juntamente com outros exames e/ou aspectos clínicos para maior precocidade do diagnóstico, diferenciar casos mais graves, entre outros. Este estudo se propõe a trazer à discussão as diferentes maneiras como o VHS têm sido utilizadas como indicador, e permitir entender como poderá ser acrescentado na rotina da oncologia. Foi realizada uma revisão integrativa da literatura em bases de dados, no período de 2018 a 2023. Dos 1.008 artigos identificados inicialmente, 21 foram selecionados para a escrita do trabalho. Os artigos foram classificados quanto o foco da sua abordagem em: diagnóstico, gravidade, prognóstico, tratamento e outros. Os estudos abordaram diferentes tipos de câncer, e foram realizados em diversos países. Como pontos a serem ressaltados, o uso do teste mostrou bons resultados para as diferentes abordagens, porém dentro das neoplasias temos grande variedade de doenças e para utilizar esses dados faz-se necessário repetir os estudos para cada doença, aumentar o número de pacientes ou realizar estudos multicêntricos para ampliar a certeza.
References
Higuchi M, Watanabe N. A rapid and accurate method for estimating the erythrocyte sedimentation rate using a hematocrit-corrected optical aggregation index. PLOS ONE.2022; 17(7), e0270977. https://doi.org/10.1371/journal.pone.0270977 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0270977
Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V.(2012). Multifaceted link between cancer and inflammation. Biosc Rep. 2012;26(11):3832-3839. https://pubmed.ncbi.nlm.nih.gov/21981137/
Fagundes IS, Matos DJ, Cervelatti EP. O papel dos macrófagos de perfil M2 no processo de metástase tumoral associado à inflamação crônica: The role of M2 profile macrophages in the process of tumor metastasis associated with chronic inflammation. Braz. J. Hea. Rev. [Internet]. 30º de novembro de 2022 [citado 26º de abril de 2024];5(6):23407-22. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/54845
Figueiredo CRLV. The unusual paradox of cancer-associated inflammation: An update. JBPML. 2019;55(3), 327–32. https://doi.org/10.5935/1676-2444.20190029
Basoli S, Cosentino M, Traversari M, Manfrini M, Tsukamoto S, Mavrogenis AF, et al. The Prognostic value of serum biomarkers for survival of children with osteosarcoma of the extremities. Curr Oncol. 2023;30(7):7043–54. https://doi.org/10.3390/curroncol30070511 https://www.mdpi.com/1718-7729/30/7/511
Peng C, Juan C, Mao W, Jinghe Y, Renli T. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients. Eur Rev Med Pharmacol Sci. 2022;26(11):3832-39. doi: 10.26355/eurrev_202206_28950. https://pubmed.ncbi.nlm.nih.gov/35731052/
Souza MT, Silva MD, Carvalho R. Integrative review: what is it? How to do it? Einstein (São Paulo). 2010;8(1), 102–6. https://doi.org/10.1590/s1679-45082010rw1134 https://www.scielo.br/j/eins/a/ZQTBkVJZqcWrTT34cXLjtBx/?lang=en
INCA. Detecção Precoce do Câncer. Ministério da saúde Instituto Nacional de Câncer José Alencar Gomes da Silva.2021. 1 ed. http://controlecancer.bvs.br/
Silva MD, Marques RB, Costa LO. Câncer de colo de útero: barreiras preventivas no século 21 / Cervical cancer: preventive barriers in the 21st century. Braz. J. Hea. Rev. [Internet]. 7º de abril de 2021 [citado 26º de abril de 2024];4(2):7610-26. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/27818
World Health Organization. Guide to early cancer diagnosis.2017. https://www.who.int/publications/i/item/9789241511940
Eshraghi M, Hosseini SJE, Razavinia FS, Noori E. Comparative study of the level of inflammatory factors of erythrocyte sedimentation rate and reactive protein c in benign and malignant thyroid nodules. PBOCI.2021;(21), 1–8. https://doi.org/10.1590/pboci.2021.019
Koshiaris C, Bruel AV, Nicholson BD, Lay-Flurrie S, Hobbs RFD, Oke JL. Clinical prediction tools to identify patients at highest risk of myeloma in primary care: a retrospective open cohort study. Br J Gen Prac. 2021; 71(706), E347–55. https://doi.org/10.3399/BJGP.2020.0697 https://www.scielo.br/j/pboci/a/Q4YX3CNrsRf57jnVfjVDf5R/?lang=en
Velidedeoglu M, Kundaktepe BP, Aksan H, Uzun H. Preoperative fibrinogen and hematological indexes in the differential diagnosis of idiopathic granulomatous mastitis and breast cancer. Medicina 2021, 57(7), 698; https://doi.org/10.3390/medicina57070698 https://www.mdpi.com/1648-9144/57/7/698
Wu A, Liang Z, Yuan S, Wang S, Peng W, Mo Y, Yang J, Liu Y. Development and validation of a scoring system for early diagnosis of malignant pleural effusion based on a nomogram. Fron Oncol. 2021:11. https://doi.org/10.3389/fonc.2021.775079
Koshiaris C, Bruel AV, Oke JL, Nicholson BD, Shephard E, Braddick M. Early detection of multiple myeloma in primary care using blood tests: A case-control study in primary care. Br J Gen Prac. 2018; 68(674), e586–93. https://doi.org/10.3399/bjgp18X698357 https://bjgp.org/content/68/674/e586
Morawska M, Dwilewicz-Trojaczek J, Stompór T, Ligocki P, Stopiński M, Sutkowski M, et al. A Stepwi+se Screening Protocol for Multiple Myeloma. J Clin Med. 2023;12(4). https://doi.org/10.3390/jcm12041345 https://www.mdpi.com/2077-0383/12/4/1345
Watson J, Salisbury C, Banks J, Whiting P, Hamilton W. Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records. Br J Can. 2019; 120(11), 1045–1051. https://doi.org/10.1038/s41416-019-0458-x https://www.nature.com/articles/s41416-019-0458-x
Ngadikun, Pradjatmo H, Nugroho KA, Pasala M, Prasetyastuti. Analysis of erythrocyte sedimentation rate order in epithelial ovarian cancer. J Can.2023;14(12), 2173–80. https://doi.org/10.7150/jca.82941 https://www.jcancer.org/v14p2173.htm
Varim C, Celik FD, Sunu C, Öztop KE, Aydin A, Yaylaci S, et al. The role of neutrophil albumin ratio in predicting the stage of non-small cell lung. Eur Rev Med Pharm Sci. 2022;26, 2900–5. https://pubmed.ncbi.nlm.nih.gov/35503633/
Singh Y, Barua SK, Trivedi S, Kashyap MP, Agrawal LK, Pathak UK, et al. Skeletal-Related Events in Renal Cell Carcinoma: Prediction with alkaline phosphatase (ALP), C-reactive protein (CRP), haemoglobin (Hb) and erythrocyte sedimentation rate (ESR) (A.C.H.E.) Score for risk stratification. Cureus. 2023; 22 Jun. https://doi.org/10.7759/cureus.40835 https://www.cureus.com/articles/148801-skeletal-related-events-in-renal-cell-carcinoma-prediction-with-alkaline-phosphatase-alp-c-reactive-protein-crp-haemoglobin-hb-and-erythrocyte-sedimentation-rate-esr-ache-score-for-risk-stratification#!/
Winarto H, Habiburrahman M, Anggraeni TD, Nuryanto KH, Julianti RA, Purwoto G, et al. The Utility of Pre-Treatment Inflammation Markers as Associative Factors to the Adverse Outcomes of Vulvar Cancer: A Study on Staging, Nodal Involvement, and Metastasis Models. J Clin Med. 2023; 12(1). https://doi.org/10.3390/jcm12010096 https://www.mdpi.com/2077-0383/12/1/96
Tekneci AK, Akçam Tİ, Kavurmacı Ö, Ergönül AG, Özdil A, Turhan K, et al. Relationship between survival and erythrocyte sedimentation rate in patients operated for lung cancer. Turk J Thor Card Surg. 2022;30(3), 381–8. https://doi.org/10.5606/tgkdc.dergisi.2022.21217
Shibuya N, Ishizuka M, Takagi K, Iwasaki Y, Hachiya H, Aoki T, et al. Relationship between preoperative erythrocyte sedimentation rate and survival after surgery in patients with colorectal cancer. Antic Res. 2018; 38(12), 6783–88. https://doi.org/10.21873/anticanres.13049 https://ar.iiarjournals.org/content/38/12/6783
Jettoo P, Tan GJS, Gerrand CH, Rankin K S. Role of routine blood tests for predicting clinical outcomes in osteosarcoma patients. J Orthop Surg. 2019; 27(2). https://doi.org/10.1177/2309499019838293
Park G, Song SY, Ahn JH, Kim WL, Lee JS, Jeong SY, et alThe pretreatment erythrocyte sedimentation rate predicts survival outcomes after surgery and adjuvant radiotherapy for extremity soft tissue sarcoma. Rad Oncol. 2019 14(1). https://doi.org/10.1186/s13014-019-1331-z https://ro-journal.biomedcentral.com/articles/10.1186/s13014-019-1331-z
Shehata M, Elkhouly E, Al-Agizy H, Gohar S, Shalaby R. Clinical Value of C-reactive Protein and Erythrocyte Sedimentation Rate in Advanced Bladder Cancer. Res Oncol. 2018; 0(0), 1–6. https://doi.org/10.21608/resoncol.2018.4152.1060 https://resoncol.journals.ekb.eg/article_17100.html
Balatoni T, Ladányi A, Fröhlich G, Czirbesz K, Kovács P, Pánczél G, et al. Biomarkers associated with clinical outcome of advanced melanoma patients reated with Ipilimumab. Pathol Oncol Res . 2020; 26(1):317–25. https://doi.org/10.1007/s12253-018-0466-9 https://link.springer.com/article/10.1007/s12253-018-0466-9
Okuhira H, Yamamoto Y, Inaba Y, Kunimoto K, Mikita N, Ikeda T, et al. Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab. Biosci. Trends, (2018);12(4), 412–18. https://doi.org/10.5582/bst.2018.01158 https://www.jstage.jst.go.jp/article/bst/12/4/12_2018.01158/_article
Hawkes EA, Loh Z, Estacio O, Chong G, Ha FJ, Gilbertson M et al. Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission. Br. J. Cancer .2018;119(5), 546–50. https://doi.org/10.1038/s41416-018-0183-x https://www.nature.com/articles/s41416-018-0183-x
